Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBT (2021 - 2025)

Krystal Biotech's EBT history spans 5 years, with the latest figure at $51.1 million for Q4 2025.

  • For Q4 2025, EBT rose 5.19% year-over-year to $51.1 million; the TTM value through Dec 2025 reached $189.5 million, up 98.7%, while the annual FY2025 figure was $189.5 million, 98.7% up from the prior year.
  • EBT for Q4 2025 was $51.1 million at Krystal Biotech, up from $48.0 million in the prior quarter.
  • Across five years, EBT topped out at $80.7 million in Q3 2023 and bottomed at -$50.0 million in Q1 2022.
  • The 5-year median for EBT is -$7.3 million (2021), against an average of $4.4 million.
  • The largest annual shift saw EBT tumbled 215.99% in 2022 before it soared 4577.79% in 2025.
  • A 5-year view of EBT shows it stood at -$21.8 million in 2021, then tumbled by 46.99% to -$32.1 million in 2022, then surged by 133.25% to $10.7 million in 2023, then skyrocketed by 356.13% to $48.6 million in 2024, then increased by 5.19% to $51.1 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's EBT are $51.1 million (Q4 2025), $48.0 million (Q3 2025), and $46.8 million (Q2 2025).